Abstract
Chelators currently employed in iron overload therapy have important side effects. Desferrioxamine (DFO), the main agent of this therapy, presents rapid renal clearance, without oral activity, which requires from patients prolonged and almost daily infusions. In this project, we aim to couple DFO to bovine serum albumin (BSA) and / or ovalbumin (OVA) through amino acids with amine or carb…